Why Is CULLINAN THERAPEUTIC (CGEM) Stock Down Today?
By the Top Tier Newswire AI Desk · September 25, 2026 at 12:14 AM ET · reviewed against 9 wire stories
CULLINAN THERAPEUTIC (CGEM) is down -8.48% in the latest session. Our newswire has captured 9 stories on CGEM across 7 sources in the last 36 hours, with AI sentiment reading mixed (avg 46/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Cullinan Therapeutics (CGEM) fell 8.48% to $15.44 in the session as the company delayed the release of multi-dose data for its rheumatoid arthritis therapy, CLN-978. The update, originally expected in the third quarter, will now be available in December. The delay has raised concerns among investors about the drug’s safety profile and development timeline.
What Happened
The stock extended its losses after the company disclosed the delay in a recent filing and through public statements. The multi-dose data for CLN-978, which targets difficult-to-treat rheumatoid arthritis, was expected to provide early insights into the drug’s potential. The postponement has intensified scrutiny over the drug’s progress and its ability to meet regulatory and market expectations. Additionally, the company has faced lingering concerns over zipalertinib, its other key therapy, despite positive Phase 3 trial results for that drug in EGFR exon 20+ lung cancer. The mixed signals have contributed to the downward pressure on the stock.
What The Data Shows
Over the past eight trading sessions, CGEM has declined 23.7% from $20.40 to $15.57. The stock has printed 24 fresh 52-week lows on September 24, 2026, indicating significant retail and institutional selling pressure. Meanwhile, the Chief Scientific Officer, Jennifer Michaelson, has sold shares on three separate occasions over the past 90 days, totaling $923K. These insider sales reflect a lack of immediate confidence in the stock’s near-term direction. The company’s fundamentals remain weak, with a market cap of $1.4B and a trailing twelve-month earnings per share of -3.47.
What To Watch
Investors should monitor the December 2026 data readouts for CLN-978 across rheumatoid arthritis, SLE, and Sjögren’s disease. These updates will be critical in determining the drug’s potential and could influence the stock’s trajectory in the coming months.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AI sentiment, last 36h · averaged over 9 stories · 46/100 neutral
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
14h agoStocktwits NewsBEARISH 32Product/PR
CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger
Additional multi-dose data for CLN-978 in difficult-to-treat rheumatoid arthritis (RA), once expected in the third quarter, will now arrive in December.
Cullinan drops after delaying early-stage trial data for arthritis therapy
Cullinan Therapeutics (CGTX) stock dips as the company delays a Phase 1 readout for its rheumatoid arthritis therapy, CLN-978. Read more here.
17h agoThe FlyBEARISH 34General
Cullinan falls after pushing rheumatoid arthritis data to December
17h agoMarketChameleonBULLISH 63Product/PR
CGEM Sets Up a Data-Heavy Q4 2026 With Three T Cell Engager Readouts Across Autoimmune Disease and AML
September 24, 2026
Cullinan Therapeutics (CGEM) outlined multiple fourth-quarter 2026 milestones, including December multi-dose regimen data for CLN-978 across SLE, RA, and Sjögren’s disease and updated December Phase 1 dose escalation data for CLN-049 in relapsed/refractory AML. The company also plans to present velinotamig multi-dose regimen data in SLE at ACR Convergence 2026 on November 8, 2026.
22h agoThe FlyBULLISH 56General
Cullinan Therapeutics outlines Q4 2026 milestones across pipeline
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren’s disease in December
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →